About Biogen Inc.
Biogen Inc. (BIIB) has been publicly traded since 1991, making it a 35-year-old public company. It operates in the Drug Manufacturers - General industry within the Healthcare sector. The company is headquartered in Cambridge, United States and employs approximately 7,500 people. With a market capitalization of $27 billion, BIIB is a large established company.
Key Statistics
- Current Price
- $185.38
- Market Cap
- $27.21B
- 52-Week High
- $202.41
- 52-Week Low
- $110.04
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
$1,000 Invested
Monthly Returns Heatmap
Annual Returns
| Year | Return | Start | End |
|---|---|---|---|
| 2026 | +5.33% | $175.99 | $185.38 |
| 2025 | +15.09% | $152.92 | $175.99 |
| 2024 | -40.91% | $258.77 | $152.92 |
| 2023 | -6.55% | $276.92 | $258.77 |
| 2022 | +15.42% | $239.92 | $276.92 |
| 2021 | -2.02% | $244.86 | $239.92 |
| 2020 | -17.48% | $296.73 | $244.86 |
| 2019 | -1.39% | $300.92 | $296.73 |
| 2018 | -5.54% | $318.57 | $300.92 |
| 2017 | +12.34% | $283.58 | $318.57 |
| 2016 | -7.43% | $306.35 | $283.58 |
| 2015 | -9.75% | $339.45 | $306.35 |
| 2014 | +21.42% | $279.57 | $339.45 |
| 2013 | +91.00% | $146.37 | $279.57 |
| 2012 | +33.00% | $110.05 | $146.37 |
| 2011 | +64.13% | $67.05 | $110.05 |
| 2010 | +25.33% | $53.50 | $67.05 |
| 2009 | +12.32% | $47.63 | $53.50 |
| 2008 | -16.32% | $56.92 | $47.63 |
| 2007 | +15.71% | $49.19 | $56.92 |
| 2006 | +8.64% | $45.28 | $49.19 |
| 2005 | -32.02% | $66.61 | $45.28 |
| 2004 | +81.50% | $36.70 | $66.61 |
| 2003 | +10.64% | $33.17 | $36.70 |
| 2002 | -51.88% | $68.93 | $33.17 |
| 2001 | +9.09% | $63.19 | $68.93 |
| 2000 | +92.94% | $32.75 | $63.19 |
| 1999 | +318.09% | $7.83 | $32.75 |
| 1998 | +36.73% | $5.73 | $7.83 |
| 1997 | +44.74% | $3.96 | $5.73 |
| 1996 | +21.79% | $3.25 | $3.96 |
| 1995 | +817.65% | $0.35 | $3.25 |
| 1994 | -63.04% | $0.96 | $0.35 |
| 1993 | -34.29% | $1.46 | $0.96 |
| 1992 | -32.69% | $2.17 | $1.46 |
Valuation
BIIB currently trades at a trailing P/E ratio of 20.7, which is considered moderate relative to the broader market. The forward P/E of 11.2 suggests analysts expect earnings to be lower in the coming year. The price-to-book ratio stands at 1.5. The price-to-sales ratio is 2.7.
Dividends
Biogen Inc. does not currently pay a dividend, choosing to reinvest earnings back into the business for growth.
Risk & Volatility
BIIB has a beta of 0.14, indicating it is less volatile than the overall market. The stock's 52-week range is $110.04 to $202.41, and it currently trades in the upper half of its 52-week range.
Analyst Ratings
Based on 30 analyst opinions, BIIB has a consensus "buy" rating. The average price target of $205.67 suggests 13.3% upside from current levels.
Frequently Asked Questions
What does Biogen Inc. do? ▼
Biogen Inc. is a Drug Manufacturers - General company operating in the Healthcare sector. The company is headquartered in Cambridge, United States.
What sector is BIIB in? ▼
BIIB operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
When did BIIB go public? ▼
Biogen Inc. went public in 1991, making it a 35-year-old public company as of 2026.
How much would $1,000 invested in BIIB 5 years ago be worth today? ▼
A $1,000 investment in BIIB five years ago would be worth approximately $696 today, representing a -30.4% return.
Does BIIB pay dividends? ▼
No, Biogen Inc. does not currently pay a dividend. The company reinvests its earnings into growth.
What is BIIB's market cap? ▼
Biogen Inc. has a market capitalization of $27 billion, classifying it as a large-cap company.
What is BIIB's P/E ratio? ▼
BIIB has a trailing P/E ratio of 20.7 and a forward P/E of 11.2, which measures how much investors are paying per dollar of earnings.
Is BIIB a buy, hold, or sell? ▼
Based on 30 opinions, BIIB has a consensus "buy" rating. The average price target is $205.67.
Last updated: 3/14/2026